Drugs Made In America Acquisition II Corp. Unit
NASDAQ: DMIIU0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Financial Services
- Industry
- Asset Management
- CEO
- Roger Bendelac
- Employees
- 2
- Headquarters
- Fort Lauderdale, United States
- IPO year
- 2025
- Market cap
- $706.6M
- Website
- https://dmaacorp.com/
Loading DMIIU…
Loading profile data…Frequently asked questions about DMIIU
What does Drugs Made In America Acquisition II Corp. Unit (DMIIU) do?
DMIIU is a Special Purpose Acquisition Company (SPAC), operating as a blank check firm established in the Cayman Islands. Its core objective is to identify and complete a merger or acquisition with an existing business. The company specifically aims to acquire targets within the pharmaceutical and drug industries, driven by the goal of reducing...
Where does DMIIU trade?
Drugs Made In America Acquisition II Corp. Unit (DMIIU) trades on the NASDAQ Global Select.
What sector is DMIIU in?
Drugs Made In America Acquisition II Corp. Unit (DMIIU) operates in the Financial Services sector, specifically in the Asset Management industry.
Who is the CEO of Drugs Made In America Acquisition II Corp. Unit?
Roger Bendelac is the chief executive officer of Drugs Made In America Acquisition II Corp. Unit (DMIIU).
Where is Drugs Made In America Acquisition II Corp. Unit headquartered?
Drugs Made In America Acquisition II Corp. Unit is headquartered in United States.
Does DMIIU pay a dividend?
Drugs Made In America Acquisition II Corp. Unit (DMIIU) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DMIIU go public?
Drugs Made In America Acquisition II Corp. Unit (DMIIU) completed its initial public offering in 2025.